Correction – Biotage AB (publ) – disclosure notice of substantial holding of shares

The disclosure notice published earlier today contained a calculation error. Right number of repurchased shares and percentages held appears below.
 
Biotage AB (publ) has as of 13 February 2012 bought back an aggregate of 5,359,956 shares under the re-purchase program resolved at the Annual General Meeting with the shareholders on 27 April 2011. The Company`s aggregated holding of own shares corresponds to 6.73 per cent of the total amount of shares and votes in the Company.

The total amount of shares outstanding, including shares held in treasury, amounts to 79,637,688.

The Board of Directors intends to propose the forthcoming Annual General Meeting to resolve that the re-purchased shares shall be cancelled.

Contact:
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

Biotage discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 4.02pm on 13 February 2012.

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world’s largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the US, UK, China and Japan. Biotage has 270 employees and had sales of 428.4 MSEK in 2011. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com